Showing results (81-90 of 93) with videos related to
Sort By:
Pageof 10
Cancer Chemotherapy and Pharmacology|November 28, 2007
Intraperitoneal gemcitabine pharmacokinetics: a pilot and pharmacokinetic study in patients with advanced adenocarcinoma of the pancreasT Clark Gamblin, Merrill J Egorin, Eleanor G Zuhowski, et al.Cancer Chemotherapy and Pharmacology|October 3, 2007
Phase I clinical trial of intrathecal gemcitabine in patients with neoplastic meningitisRonald J Bernardi, Lisa Bomgaars, Elizabeth Fox, et al.Nature Genetics|September 26, 2024
Identifying genetic variants that influence the abundance of cell states in single-cell dataLaurie Rumker, Saori Sakaue, Yakir Reshef, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2008
A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignanciesSuresh S Ramalingam, Merrill J Egorin, Ramesh K Ramanathan, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2007
Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignanciesSuresh S Ramalingam, Robert A Parise, Ramesh K Ramanathan, et al.Neuro-Oncology|March 25, 2008
Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant gliomaDavid A Reardon, Annick Desjardins, James J Vredenburgh, et al.Frontiers in Oncology|September 15, 2022
Cost-effectiveness analysis of personalised versus standard dosimetry for selective internal radiation therapy with TheraSphere in patients with hepatocellular carcinomaCarla Rognoni, Maria Rosa Barcellona, Irene Bargellini, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2008
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working GroupJoseph Gibbons, Merrill J Egorin, Ramesh K Ramanathan, et al.The Journal of Experimental Medicine|March 2, 2021
Single-cell analyses identify circulating anti-tumor CD8 T cells and markers for their enrichmentKristen E Pauken, Osmaan Shahid, Kaitlyn A Lagattuta, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2005
Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiformeDavid A Reardon, Merrill J Egorin, Jennifer A Quinn, et al.Pageof 10